Firms

Arkin Bio Ventures

Arkin Bio Ventures

arkin-capital.com

Arkin Bio Ventures is Arkin Capital’s early-stage biotechnology venture investment platform, distinct from the later clinical-stage Arkin Bio Capital fund. It supports preclinical and early clinical companies and lists three fund generations: Arkin Bio Ventures I, II and III. Pini Orbach oversees the funds as managing partner. Adar Makovski Silverstein and Avital Adler are principals on the third fund’s management team. Investments in neuroscience, including chemogenetic gene-therapy developer Redpin Therapeutics, are described in the manager’s portfolio; their exact financing records remain under review. Two previously imported HI-Bio Series B links have been corrected to Arkin Bio Capital, the participant named in HI-Bio’s original financing announcement.

Founded
—
Type
Venture capital

Funds3

  • Arkin Bio Ventures I—

    Early-stage biotechnology. Manager timeline identifies 2016; exact announcement day and closed capital are not asserted.

  • Arkin Bio Ventures II—

    Early-stage biotechnology. Manager timeline identifies 2020; exact announcement day and closed capital are not asserted.

  • Arkin Bio Ventures III—

    Preclinical and early clinical biotechnology. Manager timeline identifies 2025; exact announcement day and closed capital are not asserted.

Team

Operations and support

Adar Makovski SilversteinAdar Makovski SilversteinPrincipal
Avital AdlerAvital AdlerPrincipal
Pini OrbachPini OrbachManaging Partner

Co-investing

No co-investors on record yet.

Investments

No investment rounds on record yet.